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GENERIC-NAME PRESCRIPTION AND PERCEIVED QUALITY
IN THE DEMAND FOR PHARMACEUTICALS IN ARGENTINA
Maceira DA, Kurtzbart R
Center for the Study of the State and Society, Buenos Aires,
Argentina
OBJECTIVES: Pharmaceutical markets are examples of imper-
fect competition, based on product differentiation associated to
perceive quality under a patent scheme. In Argentina, the 25649
law in 2002 deﬁned the “duty to prescribe medicines by the
generic name of their active principle”, changing the prior nor-
mative that allow brand names in prescriptions. The aim of the
initiative was to provide the opportunity for substitution based
on prices of products therapeutically equivalent, triggering price
reductions and higher access to pharmaceuticals. Considering
pharmaceutical markets as an array of sub-markets with non-
homogeneous characteristics, this paper focuses on the analysis
of two therapeutic classes: hypolipemiants and calcium blockers.
The objective is to measure the impact of the normative on
prices, by using a data set of monthly sales by ﬁrm and by brand
for the period July 1999–June 2004. METHODS: By using a dis-
crete choice model of product differentiation, the econometric
implementation shows a panel data analysis where each ﬁrm’s
market share is explained by price and non-price characteristics,
plus a dummy variable that account for normative switch, cor-
rected by macroeconomic variables (exchange rates and eco-
nomic activity ﬂuctuations). Among non-market characteristics,
the estimations consider age of the product as a proxy or repu-
tation builder, manufacturer position in the local market, and
nature of the capital (local or multinational ﬁrm). RESULTS:
Results show that product age is signiﬁcant and positive expla-
nation for market share in both classes studied, while foreign
capital and industry leadership have the expected sign just for
one of the markets considered. Additionally, price is negative and
signiﬁcant at 99%. CONCLUSION: However, price sensitivity
to the price increased only about 0.9% and 0.3% for each
market because of the normative change, which shows perceived
quality as the main explanation for demand, and rejecting the
hypothesis of truncated demand function based on loyalty.
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RACIAL/ETHNIC DISPARITIES IN PRESCRIPTION DRUG
UTILIZATION AND OUT-OF-POCKET COSTS
Bhandari A
University of Maryland, School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: There is very limited existing research on
national-level racial/ethnic disparities in overall prescription
drug utilization and out-of-pocket prescription drug (OOP PD)
expenditures in working-age adults. This analysis used the 2002
Medical Expenditure Panel Survey (MEPS) to study pharma-
ceutical use and OOP PD expenditure differences across racial/
ethnic groups, in a nationally representative population of Asian,
Black, Hispanic and White adults age 18–64. METHODS: The
predisposing, enabling, and need framework of the Andersen
Behavioral Model of Health Services Utilization was used to
guide hypotheses and variable selection. MEPS is a national
survey of health care use, expenditures, sources of payment, and
insurance coverage. A negative binomial regression model was
used to analyze the number of annual prescriptions and a two-
part model was used to model annual OOP PD expenditures.
These models adjusted for various demographic, health status,
income and insurance coverage variables. RESULTS: In unad-
justed analyses, Whites ﬁlled an average of 10.1 medicines in
2002; this was signiﬁcantly greater than drug use for Hispanics
(4.72), Blacks (8.55) and Asians (4.1), p-value < 0.05 for all com-
parisons. After adjusting for predisposing, enabling and need
factors, statistically signiﬁcant differences in levels of medication
use across racial/ethnic groups remained: compared to Whites,
Asians used 47.8%, Blacks 26.2% and Hispanics 39.1%, fewer
prescription drugs per year. In unadjusted analyses, Whites had
OOP costs of $218, compared to $110, $163, and $75 for His-
panics, Blacks, and Asians, respectively. After adjustment, among
subjects with any drug expenditures, these racial/ethnic groups
had 38%, 30% and 56% lower expenditures compared to
Whites, respectively. CONCLUSION: This study found signi-
ﬁcant disparities in pharmaceutical use across racial/ethnic
groups, even after controlling factors such as income, insurance
coverage and health status. Pharmaceutical therapy is critical to
health care and lower utilization among minorities may explain
why these groups suffer disproportionately from the effects of
chronic diseases.
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THE IMPACT OF MAIL ORDER PHARMACY IN DRUG
UTILIZATION AND REIMBURSEMENT IN A LARGE
RETIREMENT SYSTEM
Seoane-Vazquez E, Rodriguez-Monguio R, Visaria J
Ohio State University, Columbus, OH, USA
OBJECTIVES: The objective of this study was to compare drug
utilization and drug net reimbursement for a retiree patient pop-
ulation using mail order pharmacy services with the results of a
model simulating the effect of community pharmacy services for
the same population. METHODS: The data source was a large
public employees’ retirement system pharmacy claims data for
the period January 2000–September 2005. The unit of analysis
was the course of drug therapy (CDT), representing the combi-
nation of unique patient ID, and unique. A retrospective cohort
study was comparing utilization and reimbursement patterns in
community vs. mail order pharmacy. A simulation model was
employed to assess drug utilization and reimbursement in com-
munity pharmacy using mail order pharmacy claim data. Drug
claims were aggregated to obtain a set of courses of drug therapy
(CDTs) representing unique patient IDs and unique drug name,
formulation, and strength. The model assumed that CDT in com-
munity pharmacy would have utilization patterns similar to
those found in mail order pharmacy. RESULTS: A total of
796,859 CDTs for 138,654 patients were included in the study.
Patients had an average of 6.7 CDTs, with 11.4 claims per CDT
and an average of 2.5 years in therapy. The study found high
drug therapy discontinuation ratios, with 78.1% of all CDTs dis-
continued during the study period. The use of mail order was
estimated to result in an increase of 3.4% in drug utilization in
comparison with community pharmacy. The effect of mail order
pharmacy on utilization varied by drug and by therapeutic class.
CONCLUSION: Mail order pharmacy increases drug utiliza-
tion. Pharmacy beneﬁt managers should implement programs to
identify and manage patients, diseases and drug therapies with
high therapy discontinuation. Decision makers should carefully
evaluate the utilization and cost effects that result from the
implementation of mail order pharmacy programs.
PHP10
ASSESSING PAYER AND EMPLOYER PERSPECTIVES RELATED
TO VALUE IN HEALTH CARE
Bresnahan BW1, Carlson R1, Garrison LP1, Carpenter G2,
Neumann PJ3, Sullivan SD1
1University of Washington, Seattle, WA, USA, 2WorkWell Systems, Inc,
Aliso Viejo, CA, USA, 3Tufts-New England Medical Center, Boston,
MA, USA
A25Abstracts
OBJECTIVES: To conduct a study to assess value perceptions
and the evidence needs for key stakeholders of medical product
manufacturers, including payers and employers. This study was
a structured, qualitative assessment of inﬂuential U.S. health
plans and companies. METHODS: Telephone survey interviews
were used to collect data from ﬁfteen private U.S. payer re-
presentatives and payer-related experts. Phone and in-person
interviews were conducted with twenty-six U.S. employer 
representatives. Working behavioral assumptions were con-
structed for the payer and employer groups, and stakeholder-
speciﬁc discussion guides were used to facilitate the survey 
interviews. RESULTS: The top payer ﬁndings suggest that health
plans are most interested in clinical safety, efﬁcacy, and effec-
tiveness evidence. Payers’ demands are increasing for more 
clinical utility and clinical performance studies providing 
comparative information for medical products. Cost and cost-
effectiveness were identiﬁed as important but secondary con-
siderations for coverage and reimbursement decisions. The
employers surveyed exhibited substantial diversity in their
approach to providing health care beneﬁts for employees. The
majority of employers and payers reported that consumer-
directed health care (CDHC) plans are increasing in scope and
will play a larger role moving forward. Most reported that the
effects of CDHC on costs and long-term health outcomes are
unclear. Recent trends associated with health care costs increas-
ing faster than inﬂation contribute to employers’ difﬁculty with
deﬁning “value in health care” and to their challenges associated
with evaluating return on investment for health care expendi-
tures. CONCLUSION: U.S. employers and payers are struggling
with clearly deﬁning the concept of medical product value.
Payers rely on phase III randomized controlled trials as their
primary evidence source for covering medical products, yet
request additional post-marketing comparative studies. Employ-
ers are largely engaged in cost-shifting to employees and are
trying to select younger and healthier workforces to reduce their
health care expenditures.
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THE VOLUNTARY INCENTIVE STRUCTURE OF PEDIATRIC
EXCLUSIVITY AND ITS IMPACTS ON PHARMACEUTICAL
INDUSTRY BEHAVIOR AND GENERIC DRUG ENTRIES
Rhee J
UCLA, Los Angeles, CA, USA
OBJECTIVES: The FDA Modernization Act of 1997 created a
six-month of market exclusivity extension in exchange for phar-
maceutical companies’ pediatric studies for the drugs of poten-
tial beneﬁts to the pediatric population. This study examines
how the voluntary incentive structure of the exclusivity has
impacted on the pharmaceutical industry’s efforts to obtain the
exclusivity and how the rule has been used to delay generic
entries for the exclusivity period. METHODS: By using 63 drugs
whose patent expired between 1999 and 2003, obtained from
the FDA, several descriptive analyses were performed. The per-
centage of drugs with pediatric exclusivity was described by
several important factors, especially focusing on main use of the
drugs. Next, all the drugs were divided into two groups—drugs
with exclusivity vs. no exclusivity—and then generic competition
degree was presented by each group for two years following the
initial patent expiration of each drug. RESULTS: A bigger ﬁrm
was good at ﬁling the exclusivity that needs additional clinical
study (p < 0.05). The competition level in each drug’s therapeu-
tic class was positively associated with having the exclusivity.
The drugs with exclusivities were more likely to treat chronic
conditions that include many blockbuster drugs. The ﬁrms have
applied for pediatric extension over the drugs with larger market
size (p < 0.01). For pediatric exclusivity group, there were no
generic competitors until six months and then there was a dra-
matic increase of generic entries after the exclusivity expired
whereas no-pediatric group didn’t show notable increasing trend
during the observation period. CONCLUSION: The market size
of a drug was the most important factor to acquire the pediatric
exclusivity that has been a tool for an originator ﬁrm to delay
generic competition. It implies the incentive structure based on
willingness of industry has not always achieved the primary goal
of “safety of children”.
PHP12
DIFFERENCES IN CHRONIC DISEASE CARE OF
PRE_MEDICARE INDIVIDUALS BETWEEN METROPOLITAN
AND NON-METROPOLITAN SETTINGS
Raoﬁ S
Centers for Disease Control and Prevention, Hyattsville, MD, USA
OBJECTIVES: Differences between metropolitan and non-
metropolitan setting in the management of chronic conditions 
in patients 55 to 64 years of age can result in higher morbidity
rates in non-metropolitan areas. We will look at the association
between the geographic setting and indicators of care manage-
ment for visits in this population. METHODS: Data from the
National Ambulatory Medical Care and National Hospital
Ambulatory Medical Care (outpatient department) surveys were
combined for years 2001 to 2004. NAMCS and NHAMCS
collect visit data from medical records of randomly selected
physician ofﬁces, hospital outpatient departments, and hospital
emergency departments during randomly selected time periods
through the year. A metropolitan area is an urban area with a
core population of at least 50,000. Visit data were weighted by
the inverse of selection probability and used to provide annual
average estimates. Visits having diagnoses codes for hyperten-
sion, diabetes, COPD, heart disease, stroke, and cancer were
selected based on the ICD-9-CM codes. Number of chronic dis-
eases, medications mentioned, therapeutic and preventive ser-
vices performed, and diagnostic procedures ordered per visit
were compared between metropolitan and non-metropolitan set-
tings. SUDAAN software was used to develop a Poison regres-
sion model to perform the comparisons. Source of payment,
gender, and race for patients were included in the model as
covariates. The effect of the number of previous visits on the out-
comes will be examined in future. RESULTS: Although rural
visits had a higher number of chronic conditions (1.14 vs. 1.11,
p < 0.05), they had a smaller number of therapeutic and pre-
ventive services performed per visit (1.22 vs. 2.73, p < 0.01) and
had a lower number of diagnostic and screening procedures
ordered per visit (2.61 vs. 3.04, p < 0.05). CONCLUSION: The
differences in care management in the years preceding Medicare
eligibility could have implications for utilization of services once
this population enrolls in Medicare.
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THE TRENDS IN PRESCRIBING OF HERBAL MEDICINES IN
AMBULATORY SETTINGS IN THE UNITED STATES 1993–2004
Pathak P, Martin BC
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: The use and awareness of herbal medicines has
been on the rise. Although most of these products are over the
counter (OTC), it is less known how often they are recom-
mended during ofﬁce-based physician visits. Purpose: The objec-
tive of this study was to investigate the trends in prescribing of
herbal medicines in the ambulatory medical setting in the U.S.
METHODS: This study was a retrospective analysis of the
National Ambulatory Medical Care Survey (NAMCS) and 
